Axoltis Pharma’s Breakthrough in Neurodegenerative Disease Research, Supported by InSilicoTrials
Axoltis Pharma is at the forefront of developing treatments for neurodegenerative diseases, with their phase 1b clinical trial of NX210c marking a notable achievement in the field. This peptide drug candidate has shown promising results following a successful phase 1a